ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MDNA Medicenna Therapeutics Corporation

0.157
0.00 (0.00%)
25 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Medicenna Therapeutics Corporation NASDAQ:MDNA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.157 0.1565 0.1612 0 01:00:00

Form AW - Amendment Withdrawal Request

22/04/2024 9:40pm

Edgar (US Regulatory)


April 22, 2024

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

United States of America

 

Re: Medicenna Therapeutics Inc.
  Application for Withdrawal
  Post-Effective Amendment No. 1 to Form F-3 (File No. 333-269868)
  Filed April 16, 2024 under EDGAR code F-3/A

 

Ladies and Gentlemen:

 

In accordance with Rule 477(a) under the Securities Act of 1933, as amended, and as requested by the staff of the Securities and Exchange Commission (the “SEC Staff”), Medicenna Therapeutics Inc. (the “Company”) hereby respectfully requests the withdrawal of its post-effective amendment no. 1 to Form F-3 (File No. 333-269868) filed on April 16, 2024 because it was inadvertently filed under the incorrect EDGAR code for pre-effective amendments, “F-3/A”, rather than “POS AM”.

 

As requested by the SEC Staff, post-effective amendment no. 1 to the Form F-3 will be re-filed under the correct EDGAR code.

 

If you have any questions or require further information, please do not hesitate to contact Thomas Rose of Troutman Pepper Hamilton Sanders LLP, the Company’s outside counsel, at (757) 687-7715.

 

Sincerely,

 

Medicenna Therapeutics Inc.

 

/s/ David Hyman                    

David Hyman

Chief Financial Officer


1 Year Medicenna Therapeutics Chart

1 Year Medicenna Therapeutics Chart

1 Month Medicenna Therapeutics Chart

1 Month Medicenna Therapeutics Chart

Your Recent History

Delayed Upgrade Clock